



EXPRESS MAIL NO.: EV 654 849 661 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	J. Flechtner et al.	Confirmation No.:	7221
Application No.:	10/820,067	Art Unit:	1642
Filed:	April 8, 2004	Examiner:	Tidwell, Judy Lille
For:	HEAT SHOCK PROTEIN-BASED VACCINES AND IMMUNOTHERAPIES	Attorney Docket No.:	8449-406-999

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.56 AND § 1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references **A01-A19**, **B01-B17**, and **C01-C113**, which are listed on the attached List of References Cited by Applicant. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and published U.S. applications (*i.e.*, references A02-A19) are not submitted herewith. Copies of references **A01**, **B01-B17** and **C01-C113** are submitted herewith.


Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: April 12, 2006



32,605

Adriane M. Antler


(Reg. No.)

**JONES DAY**

222 E. 41<sup>st</sup> Street

New York, New York 10017

(212) 326-3939



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.  
**8449-406-999**

APPLICATION NO.  
**10/820,067**

APPLICANT  
**Fletcher et al.**

FILING DATE  
**April 8, 2004**

ART UNIT  
**1642**

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	10/170,738	06/13/02	Rothman et al.	
	A02	2003/0166530	09/04/03	Rothman et al.	
	A03	2004/0043419	03/04/04	Rothman et al.	
	A04	2005/0202033	09/15/05	Flechner et al.	
	A05	5,348,945	09/20/94	Berberian et al.	
	A06	5,498,538	03/12/96	Kay et al.	
	A07	5,541,109	07/30/96	Searfoss	
	A08	5,750,119	06/12/98	Srivastava	
	A09	5,837,251	11/17/98	Srivastava	
	A10	5,935,576	08/10/99	Srivastava	
	A11	5,961,979	10/05/99	Srivastava	
	A12	5,962,262	10/5/1999	Hillman et al.	
	A13	5,985,270	11/16/99	Srivastava	
	A14	5,997,873	12/07/99	Srivastava	
	A15	6,017,540	01/25/00	Srivastava et al.	
	A16	6,030,618	02/29/00	Srivastava	
	A17	6,048,530	04/11/00	Srivastava	
	A18	6,127,393	10/3/2000	Fernandez-Pol	
	A19	6,663,868	12/16/2003	Rothman et al.	

**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	EP 0 538 952	04/28/93	Yeda Research and Development Co. Ltd.		
	B02	WO 89/04871	06/01/89	Imperial Cancer Research Technology Limited		
	B03	WO 93/17712	09/16/93	Biocine Scalvo Spa		
	B04	WO 94/11513	05/26/94	Medical Research Council		

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-406-999	10/820,067
	APPLICANT Fletcher et al.	
	FILING DATE	ART UNIT
	April 8, 2004	1642

### FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B05	WO 94/29459	12/22/94	Whitehead Research for Biomedical Research		
	B06	WO 95/24923	09/21/95	Mount Sinai School of Medicine at the City University of New York		
	B07	WO 96/10411	04/11/96	Mount Sinai School of Medicine at the City University of New York		
	B08	WO 97/06821	02/20/97	Sloan-Kettering Institute for Cancer Research		
	B09	WO 97/06685	02/27/97	Sloan-Kettering Institute for Cancer Research		
	B10	WO 97/10000	03/20/97	Fordham University		
	B11	WO 97/10001	03/20/97	Fordham University		
	B12	WO 97/10002	03/20/97	Fordham University		
	B13	WO 97/26910	07/31/97	Max-Delbruck Centrum for Molekulare Medizin		
	B14	WO 98/23735	06/04/98	Stressgen Biotechnologies Corp.		
	B15	WO 98/35705	08/20/98	Whitehead Research for Biomedical Research		
	B16	WO 99/22761	05/14/99	Sloan-Kettering Institute for Cancer Research		
	B17	WO 99/42121	08/26/99	University of Miami		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ANDERSON, 1998, "Human gene therapy", Nature 392(6679 Suppl):25-30	
	C02	ARNOLD et al., 1995, "Cross-priming of Minor Histocompatibility Antigen-specific Cytotoxic T Cells upon Immunization with the Heat Shock Protein gp96." J. Exp. Med. 182:885-9.	
	C03	AUGER et al., 1996, "HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins." Nature Medicine 2:306-310.	
	C04	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming." Euro. J. Immunol. 22:1365-1372.	
	C05	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin. Exp. Immunol. 98:224-228.	
	C06	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DnaK proteins requires cross-linking with antigen." Clin. Exp. Immunol. 98:229-233.	
	C07	BAUER et al., 1995, "Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7." Scand. J. Immunol. 42:317-323.	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-406-999	10/820,067
	APPLICANT Fletcher et al.	
	FILING DATE	ART UNIT
	April 8, 2004	1642

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C08	BLACHERE & SRIVASTAVA, 1995, "Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors." Seminars in Cancer Biology 6:349-355.	
	C09	BLACHERE et al., 1993, "Heat shock protein vaccines against cancer." J. Immunother. 14(4):352-356	
	C10	BLACHERE et al., 1997, "Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity." J. Exp. Med. 186:1315-1322.	
	C11	BLOND-ELGUINDI et al., Affinity Panning of a Library of Peptides Displayed on Bacteriophages Reveals the Binding Specificity of BiP." Cell 75:717-728 (1993).*	
	C12	BORRAS-CUESTA et al., 1987, "Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells." Eur. J. Immunol. 17:1213-1215	
	C13	CASTELLI et al., 2001, "Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells." Cancer Res. 61(1):222-227	
	C14	CHEN et al., 2000, "Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene." Cancer Res. 60(4):1035-1042	
	C15	COX et al., 1988, "Orientation of epitopes influences the immunogenicity of synthetic peptide dimers." Eur. J. Immunol. 18:2015-2019	
	C16	CZAR et al., 1997, "Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus." Biochemistry 36:7776-7785.	
	C17	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers." Proc. Natl. Acad. Sci. USA 89:3439-3442.	
	C18	DEL GUIDICE, 1994, "Hsp70: a carrier molecule with built-in adjuvanticity." Experientia 50:1061-1066.	
	C19	DeNAGEL & PIERCE et al., 1993, "Heat shock proteins in immune responses." Critical Reviews In Immunology 13:71:81.	
	C20	DILLMAN et al., 1995, "Heat Shock Proteins and Ischemic Injury." J. Cell. Biochem., Suppl. 19B, p. 190.	
	C21	EDGINGTON, 1995, "Therapeutic applications of heat shock proteins." Biotechnol. 13:1442-1444.	
	C22	FEDOSEYEVA et al., 2001, "CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice." J. Immunol. 164(11):5641-5651	
	C23	FELDWEIG & SRIVASTAVA, 1995, "Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96." Int. J. Cancer 63:310-314	
	C24	FLAJNIK et al., 1991, "Which came first, MHC Class I or Class II?" Immunogenetics 33:295-300	
	C25	FLYNN et al., 1989, "Peptide-dependent stimulation of the ATPase activity of the molecular chaperone BiP is the result of conversion of oligomers to active monomers." Science 245:385-390.	
	C26	FRANCIS et al., 1987, "Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants." Nature 330:168-170	
	C27	GALIGNIANA et al., 1998, "Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton." Mol. Endo. 12:1903-1913.	
	C28	GETHING, et al., 1995, "Binding Sites for Hsp70 Molecular Chaperones in Natural Proteins." Cold Spring Harb. Symp. Quant. Biol. 60:417-28.	
	C29	GIBOA, 1996, "Immunotherapy of cancer with genetically modified tumor vaccines." Seminars in Oncology 23:101-107.	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-406-999	10/820,067
	APPLICANT Fletcher et al.	
	FILING DATE	ART UNIT
	April 8, 2004	1642

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C30	GRAGEROV et al., 1994, "Different peptide binding specificities of hsp70 family members." J. Mol. Biol. 235:133-135.	
	C31	GRAGEROV et al., 1994, "Specificity of DnaK-peptide binding." J. Mol. Biol. 235:848-854.	
	C32	GREENE et al., 1995, "Effect of nucleotide on the binding of peptides to 70-kDa heat shock protein." J. Biol. Chem. 270(7):2967-2978.	
	C33	HEIKE et al., 1996, "Heat shock protein-peptide complexes for use in vaccines." J. Leukoc. Biol. 60(2):153-158	
	C34	HEIKEMA et al., 1997, "Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides." Immunol. Lett. 57(1-3):69-74	
	C35	HINDS et al., 1987, "Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines." Mol Cell Biol. 7(8):2863-2869	
	C36	HOHFELD et al., 1995, "Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle." Cell 83:589-598.	
	C37	HUANG et al., 2000, "In Vivo Cytotoxic T Lymphocytes Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is CD4.sup.30 T Cell Independent." J. Exp. Med. 191:403-408	
	C38	JAATTELA, 1995, "Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells." Int. J. Cancer, 60 (5), pp. 689-693.	
	C39	JAKOB et al., 1996, "Assessment of the ATP binding properties of Hsp90." J. Biol. Chem. 271:10035-10041.	
	C40	JINDAL, S., 1996, "Heat shock proteins: applications in health and disease." Trends Biotechnol. 14:17-20.	
	C41	KONEN-WAISMAN et al., 1999, "Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection." J. Infect. Dis. 179(2):403-413	
	C42	LEWIS et al., 1999, "Pilot study of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex(HSPPC-96) in patients with resected pancreatic adenocarcinoma." Meeting Abstract, Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 18:A1687	
	C43	LI, Z. et al., 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation." EMBO J. 12:3143-51.	
	C44	LITTLE, et al., 1994, "The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications." Critical Reviews in Eukaryotic Gene Expression, 1994 4(1) pp. 1-18.	
	C45	LOPEZ-GUERRERO et al., 1993, "Modulation of adjuvant arthritis in Lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein." Infect. Immun. 61(10):4225-4231	
	C46	LOVETT et al., 1993, "Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes." J. Virol. 67(10):5849-5858	
	C47	LOWRIE et al., 1994, "Towards a DNA vaccine against tuberculosis." Vaccine 12:1537-1540.	
	C48	LOWRIE et al., 1995, "Mycobacterium Lepae HSP65 Vaccinates mice against Tuberculosis when Expressed from the Cloned Gene in Transplanted Bone Marrow Cells." J. Cell. Biochem. Suppl. 0(19b):220.	
	C49	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors." J. Exp. Med. 178:343-348.	
	C50	LUKACS et al., 1994, "Protection against tumours by mycobacterial heat shock protein gene." Cancer Gene Therapy, 1:217.	
	C51	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules." J. Eur. Immunol. 21:2297-2302.	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-406-999	10/820,067
	APPLICANT Fletcher et al.	
	FILING DATE	ART UNIT
	April 8, 2004	1642

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C52	MASTRANGELO et al., 1996, "Gene therapy for human cancer: an essay for clinicians." Seminars in Oncology, 23:4-21.	
	C53	MCCARTY et al., 1995, "The role of ATP in the functional cycle of the DnaK chaperone system." J. Mol. Biol. 249:126-137.	
	C54	MELCHER et al., 1998, "Tumor Immunogenicity is Determined by the Mechanism of Cell Death Via Induction of Heat Shock Protein Expression." Nature Medicine 4:581-587	
	C55	MELNICK, et al., 1992, "The endoplasmic reticulum stress protein GRP94 in addition to BiP, associates with unassembled immunoglobulin chains." J. of Biochem. 267:21303-21306.	
	C56	MENG et al., 1999, "Tumor suppressor gene as targets for cancer therapy." Gene Therapy of Cancer, Lattime and Gerson, Eds., Academic Press, Chap. 1, pp. 3-20	
	C57	MINAMI et al., 1996, "Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog, Hsp40." J. Biol. Chem. 271:19617-19624.	
	C58	MOROI, 2000, "Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70." Proc Natl Acad Sci U S A 97(7):3485-90	
	C59	MULTHOFF et al., 1995, "A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells." Int. J. Cancer 61:272-279.	
	C60	MUNRO AND PELHAM, 1987, "A C-terminal signal prevents secretion of luminal ER proteins." Cell, 480:899-907.	
	C61	MUSTAFA et al., 1993, "Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae." Infection and Immunity 61:5294-5301.	
	C62	NADEAU et al., 1992, "83-kilodalton heat shock proteins of trypanosomes are potent peptide-stimulated ATPases." Protein Science 1:970-979.	
	C63	NADEAU et al., 1992, "Hsp90 chaperonins possess ATPase activity and bind heat shock transcription factors and peptidyl prolyl isomerases." J. Biol. Chem. 268:1479-1487.	
	C64	NGO et al., 1994, "Computational Complexity Protein Structure Prediction and the Levinthal Paradox." Birkhauser Boston, vol. 14, pp. 491-495	
	C65	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94." Proc. Natl. Acad. Sci. USA 93:6135-6139.	
	C66	NILSSON et al., 1992, "Fusion proteins in biotechnology and structural biology." Curr. Opin. Struct. Biol. 2:569-575	
	C67	NYGREN et al., 1994, "Engineering proteins to facilitate bioprocessing." Trends Biotechnol. 12(5):184-188.	
	C68	OMURA et al., 1979, "Herbimycin, a new antibiotic produced by a strain of Streptomyces." J. Antibiotics 32:255-261	
	C69	PALLEROS et al., 1993, "ATP-induced protein-Hsp70 complex dissociation requires K <sup>+</sup> but not ATP hydrolysis." Nature 365:664-666.	
	C70	PARDOLL, 1993, "New strategies for enhancing the immunogenicity of tumors." Current Opinion in Immunology 5:719-725.	
	C71	PARTIDOS et al., 1991, "Immune responses in mice following immunization with chimeric synthetic peptides representing B and T cell epitopes of measles virus proteins." J. Gen. Virol. 72:1293-1299	
	C72	PELHAM, 1988, "Evidence that luminal ER proteins are sorted from secreted proteins in a post-ER compartment." EMBO J. 7:913-918.	
	C73	PERRAUT, 1993, "Successful primate immunization with peptides conjugated to purified protein derivative or	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>8449-406-999</b>	APPLICATION NO. <b>10/820,067</b>
	APPLICANT <b>Fletcher et al.</b>	
	FILING DATE <b>April 8, 2004</b>	ART UNIT <b>1642</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		mycobacterial heat shock proteins in the absence of adjuvants." Clin. Exp. Immunol. 93:382-386.	
	C74	PIDOUX et al., 1992, "Analysis of the BiP gene and identification of an ER retention signal in Schizosaccharomyces pombe." EMBO J. 11:1583-1591.	
	C75	PLUMIER et al., 1995, "Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery." J. Clin. Invest. 95 (4), pp. 1854-1860.	
	C76	PORGADOR et al., 1994, "Immunotherapy of tumor metastasis via gene therapy." Nat. Immun. 13:113-130.	
	C77	RETZLAFF et al., 1994, "Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 secretion in macrophage cultures." Infect. Immun. 62:5689-5693.	
	C78	RIDDELL et al., 1996, "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients." Nature Medicine 2:216-223	
	C79	ROSENBERG et al., 1996, "T7 Select Phage Display System: A powerful new protein display system based on Bacteriophage T7." inNovations (newsletter of Novagen, Inc.) No. 6, pp. 1-6.	
	C80	SATO et al., 1994, "70 kDa heat shock protein as a tumor antigen and a target for the host's anti-tumor resistance by cytotoxic T lymphocytes." Proc. Annu. Meet. Am. Assoc. Cancer Res. 35:A2959.	
	C81	SCHEERLINCK et al., 1993, Redistribution of a murine humoral immune response following removal of an immunodominant B cell epitope from a recombinant fusion protein." Mol. Immunol. 30:733-739	
	C82	SCHMID et al., 1994, "Kinetics of molecular chaperone action." Science 263:971-973.	
	C83	SILVA AND LOWRIE, 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis." Immunology 82:244-248.	
	C84	SRIVASTAVA & MAKI, 1991, "Stress-induced proteins in immune response to cancer." Current Topics in Microbiology and Immunology 167:109-123.	
	C85	SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy." Curr. Opin. Immunol. 6(5):728-732	
	C86	SRIVASTAVA et al., 1986, "Tumor rejection antigens of chemically induced sarcomas of inbred mice." Proc. Natl. Acad. Sci. USA 83:3407-3411.	
	C87	SRIVASTAVA, 1993, "Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation." Adv. Cancer Res. 62:153-177.	
	C88	SRIVASTAVA, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm." Experientia 50:1054-1060.	
	C89	SRIVASTAVA, 2002, "Interaction of Heat Shock Proteins with Peptides and Antigen Presenting Cells: Chaperoning of the Innate and Adaptive Immune Response." Ann. Rev. Immunol. 20:395-425	
	C90	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors." Proc. Natl. Acad. Sci USA 84:3807-3811	
	C91	SUTO, et al., 1995, "A Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned Peptides." Science 269:1585-7.	
	C92	SUZUE, et al., 1996, "Adjuvant-Free hsp Fusion Protein System Elicits Humoral and Cellular Immune Responses to HIV-1 p24.sup.1." J. Immunol. 156:873-9.	
	C93	SUZUKI et al., 1991, "Regulating the retention of T-cell receptor alpha chain variants within the endoplasmic reticulum: Ca(2+)-dependent association with BiP." J. Cell Biol. 114:189-205	
	C94	TAMURA et al., 1997, "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations." Science 278:117-120.	
	C95	TARPEY, I. et al., 1994, "Human cytotoxic T lymphocytes stimulated by endogenously processed human	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-406-999	10/820,067
	APPLICANT Fletcher et al.	
	FILING DATE	ART UNIT
	April 8, 2004	1642

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif." Immunology 81:222-7.	
	C96	TAVARIA et al., 1996, "Cell Stress and Chaperones 1:23-28." Cell Stress and Chaperones 1:23-28.	
	C97	THEOBALD et al., 1995, "Targeting p53 as a general tumor antigen." Proc. Natl. Acad. Sci. USA 92(26):11993-11997	
	C98	THOMSON et al., 1995, "Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design." Proc. Natl. Acad. Sci. USA 92(13):5845-5849	
	C99	THOMSON et al., 1996, "Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes." J. Immunol. 157(2):822-6	
	C100	TODRYK et al., 1999, "Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake." J. Immunol. 163:1398-1408	
	C101	UDONO et al., 1994, "Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70." J. Immun. 152, pp. 5398-5403.	
	C102	UDONO, et al., 1993, "Heat shock protein 70-associated peptides elicit specific cancer immunity." J. Exp. Med. 178:1391-6.	
	C103	UDONO, et al., 1994, "Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8+ T Cells in vivo." Proc. Natl. Acad. Sci. 91:3077-81.	
	C104	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein." Proc. Natl. Acad. Sci. USA 83:3121-3125.	
	C105	VERMA et al., 1997, "Gene therapy -- promises, problems and prospects." Nature 389(6648):239-242	
	C106	VON HEIJNE, 1985, "Signal sequences. The limits of variation." J. Mol. Biol. 184:99-105.	
	C107	WEARSCH et al., 1997, "Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide-independent." J. Biol. Chem. 272:5152-5156.	
	C108	WELLS et al., 1998, "Hsp72-mediated Augmentation of MHC Class I Surface Expression and Endogenous Antigen Presentation." Int. Immunol 10:609-617	
	C109	WHITESELL, et al., 1994, "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation." Proc. Natl. Acad. Sci. USA 91:8324-8328.	
	C110	YAMAMOTO et al., 1993, "Listeria monocytogenes-induced gamma interferon secretion by intestinal intraepithelial gamma/delta T lymphocytes." Infection and Immunity 61:2154-2161.	
	C111	YAMAZAKI et al., 1999, "Cutting Edge: Tumor Secreted Heat Shock-Fusion Protein Elicits CD8 Cells for Rejection." J. Immunol. 163:5178-5182	
	C112	ZHU et al., 1995, "Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice." Scand. J. Immunol. 42:557-563.	
	C113	ZHU et al., 1996, "Structural analysis of substrate binding by the molecular chaperone DnaK." Science 272:1606-1614.	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.